

Financial Tear Sheet

Corporate Profile

Bioverativ is a global biotechnology company dedicated to transforming the lives of people with hemophilia and other rare blood disorders through world-class research, development and commercialization of innovative therapies. Launched in 2017 following separation from Biogen Inc., Bioverativ builds upon a strong heritage of scientific innovation and is committed to actively working with the blood disorders community. The company's mission is to create progress for patients where they need it most, and its hemophilia therapies, when launched, represented the first major advancements in hemophilia treatment in more than two decades. For more information, visit www.bioverativ.com or follow @Bioverativ on Twitter.

Primary IR Contact

Investor Relations
Phone: 781-663-4360
E-mail: IR@bioverativ.com

Stock Information

BIVV (Common Stock)
Exchange NASDAQ GS (US Dollar)
Price **\$55.05**
Change (%) ▲ 0.04 (0.07%)
Volume 717,576
52 Week Low \$40.00
Market Cap \$5,951,094,185
Rolling EPS 4.22
PE Ratio 13.0462
Shares Outstanding 108,182,043
Data as of 08/18/17 4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



Recent News & Upcoming Events

08/02/17
Bioverativ Reports Second Quarter 2017 Performance

07/07/17
Bioverativ to Report Second Quarter 2017 Financial Results on August 2, 2017

07/06/17
New Data to be Presented at ISTH Underscore Bioverativ's Commitment to Advance Hemophilia Care

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/10/17	4
08/08/17	4
08/03/17	10-Q
08/02/17	8-K